Neutropenia

Management of neutropenia with ENHERTU1

  • Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated
  • Based on the severity of neutropenia, manage through treatment interruption or dose reduction
  • Of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 29.5% of patients and 16.2% had Grade 3 or 4 events. Febrile neutropenia was reported in 1.7% of patients

Dose modifications for neutropenia1

Severity Treatment Modification
Grade 3
(less than 1.0 to 0.5 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose
Grade 4
(less than 0.5 x 109/L)

Toxicity grades are in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

Dose modifications for febrile neutropenia1

Severity Treatment Modification
Absolute neutrophil count of less than 1.0 x 109/L and temperature greater than 38.3°C or a sustained temperature of ≥38°C for more than one hour
Toxicity grades are in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

Get ENHERTU Resources for You and Your Practice

ENHERTU Dosage & Administration and Recommendations for Adverse Reactions Guide
Ready to learn more about ENHERTU?